"Acetylcysteine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The N-acetyl derivative of CYSTEINE. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates.
| Descriptor ID |
D000111
|
| MeSH Number(s) |
D02.886.030.230.259 D12.125.166.230.259
|
| Concept/Terms |
Acetylcysteine- Acetylcysteine
- N-Acetyl-L-cysteine
- N Acetyl L cysteine
- N-Acetylcysteine
- N Acetylcysteine
- Mercapturic Acid
- Acid, Mercapturic
Acetylcysteine Sodium- Acetylcysteine Sodium
- Sodium, Acetylcysteine
- Acetylcysteine, Monosodium Salt
- Monosodium Salt Acetylcysteine
Fluprowit- Fluprowit
- Optipect Hustengetränk
- Hustengetränk, Optipect
- Muco Sanigen
- Sanigen, Muco
|
Below are MeSH descriptors whose meaning is more general than "Acetylcysteine".
Below are MeSH descriptors whose meaning is more specific than "Acetylcysteine".
This graph shows the total number of publications written about "Acetylcysteine" by people in this website by year, and whether "Acetylcysteine" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 3 | 1 | 4 |
| 1996 | 1 | 5 | 6 |
| 1997 | 1 | 4 | 5 |
| 1998 | 1 | 4 | 5 |
| 1999 | 1 | 5 | 6 |
| 2000 | 3 | 6 | 9 |
| 2001 | 4 | 4 | 8 |
| 2002 | 7 | 2 | 9 |
| 2003 | 4 | 6 | 10 |
| 2004 | 4 | 5 | 9 |
| 2005 | 4 | 6 | 10 |
| 2006 | 6 | 4 | 10 |
| 2007 | 3 | 7 | 10 |
| 2008 | 4 | 6 | 10 |
| 2009 | 8 | 9 | 17 |
| 2010 | 11 | 6 | 17 |
| 2011 | 9 | 4 | 13 |
| 2012 | 3 | 7 | 10 |
| 2013 | 4 | 7 | 11 |
| 2014 | 5 | 2 | 7 |
| 2015 | 8 | 4 | 12 |
| 2016 | 6 | 3 | 9 |
| 2017 | 6 | 2 | 8 |
| 2018 | 1 | 6 | 7 |
| 2019 | 4 | 4 | 8 |
| 2020 | 4 | 2 | 6 |
| 2021 | 1 | 4 | 5 |
| 2022 | 1 | 3 | 4 |
| 2023 | 1 | 7 | 8 |
| 2024 | 3 | 1 | 4 |
Below are the most recent publications written about "Acetylcysteine" by people in Profiles.
-
Low dose rifaximin combined with N-acetylcysteine is superior to rifaximin alone in a rat model of IBS-D: a randomized trial. Sci Rep. 2024 08 05; 14(1):18140.
-
Effect of N-acetyl cysteine in children with metabolic dysfunction-associated steatotic liver disease-A pilot study. J Pediatr Gastroenterol Nutr. 2024 Sep; 79(3):652-660.
-
An in vitro model for postoperative cranial nerve dysfunction and a proposed method of rehabilitation with N-acetylcysteine microparticles. Eur Arch Otorhinolaryngol. 2024 Jul; 281(7):3805-3812.
-
Association of Urinary N7-(1-hydroxyl-3-buten-1-yl) Guanine (EB-GII) Adducts and Butadiene-Mercapturic Acids with Lung Cancer Development in Cigarette Smokers. Chem Res Toxicol. 2024 02 19; 37(2):374-384.
-
An international RAND/UCLA expert panel to determine the optimal diagnosis and management of burn inhalation injury. Crit Care. 2023 Nov 27; 27(1):459.
-
Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs. BMJ Ment Health. 2023 Oct; 26(1).
-
Monogenic Causes of Cerebrovascular Disease in Childhood: A Case Series. Pediatr Neurol. 2023 Dec; 149:39-43.
-
Intravenous N-Acetylcysteine to Prevent Cisplatin-Induced Hearing Loss in Children: A Nonrandomized Controlled Phase I Trial. Clin Cancer Res. 2023 07 05; 29(13):2410-2418.
-
N-acetylcysteine for smoking cessation among dual users of tobacco and cannabis: Protocol and rationale for a randomized controlled trial. Contemp Clin Trials. 2023 08; 131:107250.
-
A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases. Eur Respir J. 2023 05; 61(5).